78 related articles for article (PubMed ID: 38423601)
21. Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma.
Belderbos RA; Vroman H; Aerts JGJV
Front Oncol; 2020; 10():777. PubMed ID: 32582537
[TBL] [Abstract][Full Text] [Related]
22. YB-1 regulates mesothelioma cell migration via snail but not EGFR, MMP1, EPHA5 or PARK2.
Schelch K; Eder S; Zitta B; Phimmachanh M; Johnson TG; Emminger D; Wenninger-Weinzierl A; Sturtzel C; Poplimont H; Ries A; Hoetzenecker K; Hoda MA; Berger W; Distel M; Dome B; Reid G; Grusch M
Mol Oncol; 2024 Apr; 18(4):815-831. PubMed ID: 36550787
[TBL] [Abstract][Full Text] [Related]
23. Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.
Yang H; Xu D; Yang Z; Yao F; Zhao H; Schmid RA; Peng RW
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824422
[No Abstract] [Full Text] [Related]
24. Comprehensive Pulmonary Rehabilitation for Patients with Malignant Pleural Mesothelioma: A Feasibility Pilot Study.
Lippi L; de Sire A; Folli A; Curci C; Calafiore D; Lombardi M; Bertolaccini L; Turco A; Ammendolia A; Fusco N; Spaggiari L; Invernizzi M
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893142
[TBL] [Abstract][Full Text] [Related]
25. Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting.
Nicolini F; Bocchini M; Angeli D; Bronte G; Delmonte A; Crinò L; Mazza M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32276524
[TBL] [Abstract][Full Text] [Related]
26. Replication DNA polymerases, genome instability and cancer therapies.
Strauss JD; Pursell ZF
NAR Cancer; 2023 Sep; 5(3):zcad033. PubMed ID: 37388540
[TBL] [Abstract][Full Text] [Related]
27. A xenotransplantable malignant deciduoid mesothelioma-cell line, D-Meso-Sonobe.
Hanamatsu Y; Saigo C; Sonobe H; Takeuchi T
Hum Cell; 2024 Jul; 37(4):1226-1228. PubMed ID: 38598046
[No Abstract] [Full Text] [Related]
28. LncRNAs and related molecular basis in malignant pleural mesothelioma: Challenges and potential.
Xu X; Li H; Xie M; Zhou Z; Wang D; Mao W
Crit Rev Oncol Hematol; 2023 Jun; 186():104012. PubMed ID: 37116816
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
Tolani B; Acevedo LA; Hoang NT; He B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
[TBL] [Abstract][Full Text] [Related]
30. POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma.
Shimizu D; Ishibashi M; Yamada T; Toda Y; Hosogi S; Ashihara E
Cancer Genomics Proteomics; 2024; 21(2):158-165. PubMed ID: 38423601
[TBL] [Abstract][Full Text] [Related]
31. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
[TBL] [Abstract][Full Text] [Related]
32. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
[TBL] [Abstract][Full Text] [Related]
33. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
34. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
35. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-adapted Multiple Myeloma Stem Cells Resist γδ-T-Cell-mediated Killing by Modulating the Mevalonate Pathway.
Sano Y; Kuwabara N; Nakagawa S; Toda Y; Hosogi S; Sato S; Ashihara E
Anticancer Res; 2023 Feb; 43(2):547-555. PubMed ID: 36697063
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
